PentixaFor

About PentixaPharm

PentixaPharm is a German radiopharmaceutical company advancing a targeted theranostic platform centered on the CXCR4 receptor. Its pipeline features two Phase-III-ready candidates: PentixaFor, a diagnostic PET imaging agent, and PentixaTher, a therapeutic radiopharmaceutical, with programs spanning hematological cancers, solid tumors, and endocrine disorders like primary aldosteronism. The company has achieved significant clinical validation, with its diagnostic administered to over 2,500 patients, and is progressing toward pivotal Phase III trials following recent FDA regulatory feedback. Backed by a team of 80 employees with deep industry expertise, PentixaPharm is positioning itself as a leader in CXCR4-targeted radiopharmaceuticals.

About PentixaPharm

PentixaPharm is a German radiopharmaceutical company advancing a targeted theranostic platform centered on the CXCR4 receptor. Its pipeline features two Phase-III-ready candidates: PentixaFor, a diagnostic PET imaging agent, and PentixaTher, a therapeutic radiopharmaceutical, with programs spanning hematological cancers, solid tumors, and endocrine disorders like primary aldosteronism. The company has achieved significant clinical validation, with its diagnostic administered to over 2,500 patients, and is progressing toward pivotal Phase III trials following recent FDA regulatory feedback. Backed by a team of 80 employees with deep industry expertise, PentixaPharm is positioning itself as a leader in CXCR4-targeted radiopharmaceuticals.

Therapeutic Areas